MOTS-c FDA PCAC July 2026: 503A Review and Research Access

The FDA's Pharmacy Compounding Advisory Committee (PCAC) is scheduled to convene on July 23, 2026 to evaluate the 503A bulk drug substance status of MOTS-c. Of the seven peptides on the July 2026 docket, MOTS-c is arguably the most scientifically distinctive: it is the only compound under review that is encoded not in the nuclear genome but in mitochondrial DNA — a classification that makes it a mitochondria-derived peptide (MDP) and places it in an entirely different biological class from the other PCAC compounds. This article covers MOTS-c's research history, its 503A regulatory position, and the specific arguments that will define the July 23 evaluation.

Research reference only. All information on this page is a summary of peer-reviewed scientific literature and regulatory documentation. It does not constitute medical or legal advice. See the MOTS-c compound library profile for full compound data, the PCAC overview article for context on all seven compounds, and the NAD+, MOTS-c, and Humanin: Mitochondrial Peptide Cluster for a comparative mechanistic overview.

What MOTS-c is — and why its origin matters

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene. Its discovery by Lee et al. (2015, Cell) established that mitochondria produce signaling peptides with systemic metabolic effects — a conceptually significant finding because mitochondria were not previously recognized as sources of hormone-like peptides acting on distant tissues.

The peptide is endogenous: MOTS-c circulates in human blood and its levels decline with age, a pattern that has been documented in both rodent models and human cohort studies. This endogenous, age-declining profile is what drove both the research interest and the compounding use that ultimately led to its nomination for the 503A docket.

The primary mechanism: AMPK activation and metabolic homeostasis

The mechanistic centerpiece of MOTS-c research is activation of AMP-activated protein kinase (AMPK), the master cellular energy sensor. Lee et al. (2015) demonstrated that MOTS-c translocates to the nucleus in response to metabolic stress, where it regulates gene expression through AMPK-dependent pathways. In skeletal muscle models, this produced increases in glucose uptake, fatty acid oxidation, and mitochondrial biogenesis — a metabolic profile that positioned MOTS-c as a research compound of significant interest for metabolic syndrome and insulin resistance models.

In the original 2015 Cell paper, MOTS-c administration in obese diet-induced mice produced significant improvements in insulin sensitivity, glucose tolerance, and body composition metrics compared to controls — findings in a high-profile journal that drove substantial downstream research interest.

Subsequent publications have extended MOTS-c's investigated mechanisms:

• Reynolds et al. (2021, Nature Aging) reported that MOTS-c levels decline in aged human subjects and that MOTS-c supplementation in aged mice improved physical performance and reduced markers of inflammaging.
• Kim et al. (2018) documented MOTS-c's role in regulating the folate cycle and one-carbon metabolism through AICAR-mediated AMPK activation, establishing a distinct mechanistic branch from the direct glucose uptake effects.
• Zhai et al. (2022) reported MOTS-c protective effects in models of sepsis-induced organ injury through reduction of inflammatory cytokine cascades.

The breadth and quality of the published MOTS-c literature — anchored by a Cell paper and supported by a Nature Aging publication — represents one of the stronger evidence bases among the seven July 2026 PCAC compounds.

The 503A framework and MOTS-c's current classification

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies that prepare individualized patient-specific prescriptions. Bulk drug substances used in these preparations must appear on an FDA-maintained positive list, be components of approved drugs, or meet specified alternative criteria. MOTS-c is currently under 503A Category 2 review — a holding classification indicating the FDA has identified questions warranting advisory committee evaluation, consistent with the other compounds in the July 2026 docket.

The July 23 evaluation is the formal opportunity for nominators — compounders, clinicians, and research advocates who have submitted clinical need documentation — to have their evidence reviewed by the committee.

The endogenous-compound and no-approved-equivalent arguments

MOTS-c holds two of the strongest individual regulatory arguments among the July 2026 PCAC compounds:

1. Endogenous status: MOTS-c is naturally produced by every human cell that contains mitochondria. Its circulating levels are measurable in human plasma, and its age-related decline has been documented in human cohort data. As an endogenous peptide, its physiological context — metabolic pathways, clearance mechanisms, receptor systems — is part of normal human biology. This informs a favorable safety context under Factor 2 of the PCAC analysis, parallel to DSIP's endogenous status on the July 24 docket.

2. No approved equivalent: No FDA-approved drug contains MOTS-c as an active ingredient. No NDA or ANDA referencing MOTS-c exists. The only approved drugs addressing metabolic syndrome and insulin resistance (metformin, GLP-1 agonists, SGLT2 inhibitors) operate through mechanisms entirely distinct from MOTS-c's mitochondrial peptide pathway. Whether these constitute "suitable commercial alternatives" for the patient populations in whom MOTS-c is compounded is a substantive question the committee will address, but the absence of a mechanism-equivalent approved drug is a meaningful distinction.

What the PCAC evaluates: four-factor analysis applied to MOTS-c

Factor 1 — Physical and chemical characteristics: MOTS-c is a 16-amino-acid peptide with a molecular weight of approximately 2174 Da, synthesized for compounding as a lyophilized powder for reconstitution and subcutaneous administration. Its stability profile and compounding feasibility are within the range of other peptides that have successfully navigated the 503A listing process.

Factor 2 — Safety and effectiveness evidence: The safety profile is favorable across the published literature, consistent with its endogenous status and the dose ranges studied in preclinical models. The effectiveness evidence — anchored by the Lee et al. (2015) Cell paper and supported by subsequent publications in aging and metabolic research journals — is among the stronger records in the July 2026 docket. Human data is limited but consistent with preclinical mechanistic predictions in the small cohorts examined.

Factor 3 — Historical use in compounding: MOTS-c has been compounded through licensed 503A pharmacies primarily in anti-aging, longevity, and metabolic health research contexts. Nominator submissions will present this usage data to the committee.

Factor 4 — Nature of the condition treated: The clinical contexts in which MOTS-c is compounded include metabolic syndrome, insulin resistance, and age-associated decline conditions for which existing approved pharmacotherapies provide partial benefit. The age-related decline in endogenous MOTS-c levels provides a mechanistic rationale for supplementation that is distinct from simply repeating a drug-class treatment already served by approved options.

Outcome scenarios following July 23, 2026

Scenario A — Upgraded to Category 1 (positive listing). The committee accepts the AMPK-activation evidence, the Cell and Nature Aging paper anchor, the endogenous status, and the absence of a mechanism-equivalent approved drug as meeting the 503A plausibility standard. 503A pharmacies continue compounding MOTS-c without disruption. Given the quality of MOTS-c's evidence base relative to other July 2026 compounds, this is a plausible outcome.

Scenario B — Maintained at Category 2. Evidence is accepted as scientifically compelling but insufficient in human clinical data volume for immediate positive listing. Regulatory holding continues with near-term access unchanged.

Scenario C — Restricted or prohibited. If the committee recommends, and FDA finalizes, exclusion from the 503A Bulks List, 503A pharmacies could not use MOTS-c as a bulk drug substance. Given its endogenous status and the quality of its evidence base, this is the least likely outcome among the July 23 compounds, but it remains a formal possibility.

Regulatory timeline

Advisory committee recommendations are not final regulatory actions. Following July 23, FDA will open a public comment period before issuing a formal determination — typically six months to over a year after the PCAC meeting. Researchers with stake in the outcome have standing to submit public comments during that window.

Summary

MOTS-c enters the July 23, 2026 PCAC evaluation with the strongest scientific evidence base of any peptide on the July docket — an original Cell paper, a Nature Aging publication, and a mechanistically coherent story rooted in endogenous biology and AMPK-mediated metabolic regulation. Its endogenous status and the complete absence of an FDA-approved mechanism-equivalent strengthen its 503A arguments. The primary uncertainty is whether the committee applies the 503A plausibility standard flexibly enough to credit strong preclinical evidence and limited-but-consistent human data, or requires a more extensive clinical trial record.

For full compound chemistry and mechanism data, see the MOTS-c compound library profile. For a comparative overview of the mitochondrial peptide cluster, see NAD+, MOTS-c, and Humanin. For the full July 2026 PCAC context, see the PCAC overview article.